Redefining the role of thiazolidinediones in the management of type 2 diabetes

References

• Department of HealthForecasting obesity to 2010Department of Health82006Available from: http://www.dh.gov.uk/en/Publicationsandstatistics/Publications/PublicationsStatistics/DH_4138630 (accessed 17 October 2008).
   Google Scholar
• AmosAFMcCartyDJZimmetPThe rising global burden of diabetes and its complications: estimates and projections to the year 2010Diabet Med199714S1S859450510
   PubMed Web of Science ®Google Scholar
• FordESPrevalence of the metabolic syndrome defined by the International Diabetes Federation among adults in the USDiabetes Care2005282745274916249550
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in AdultsExecutive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III)JAMA20012852486249711368702
   PubMed Web of Science ®Google Scholar
• DormandyJACharbonnelBEcklandDJSecondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trialLancet20053661279128916214598
   PubMed Web of Science ®Google Scholar
• BloomgardenZTThe Avandia debateDiabetes Care2007302401240817726191
   PubMed Web of Science ®Google Scholar
• WeyerCTataranniPABogardusCPratleyREInsulin resistance and insulin secretory dysfunction are independent predictors of worsening of glucose tolerance during each stage of type 2 diabetes developmentDiabetes Care200124899411194248
   PubMed Web of Science ®Google Scholar
• KahnSEThe importance of the β-cell in the pathogenesis of type 2 diabetes mellitusAm J Med2000108Suppl 6a2S8S10764844
   PubMedGoogle Scholar
• DeFronzoRA1988 Lilly Lecture The triumvirate: beta-cell, muscle, liver. A collusion responsible for NIDDMDiabetes1987376676873289989
   PubMed Web of Science ®Google Scholar
• BergmanRNAderMHueckingKVan CittersGAccurate assessment of β-cell function: the hyperbolic correctionDiabetes200251Suppl 1S212S22011815482
   PubMedGoogle Scholar
• UK Prospective Diabetes Study (UKPDS) GroupIntensive blood-glucose control with sulfonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)Lancet19983528378539742976
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupUKPDS 16. Overview of 6 years’ therapy of type II diabetes: a progressive diseaseDiabetes199544124912587589820
   PubMed Web of Science ®Google Scholar
• NestoRWThe relation of insulin resistance syndromes to risk of cardiovascular diseaseRev Cardiovasc Med20034Suppl 6S111814668699
   PubMedGoogle Scholar
• SmileyTOhPShaneLGThe relationship of insulin resistance measured by reliable indexes to coronary artery disease risk factors and outcomes–a systematic reviewCan J Cardiol20011779780511468646
   PubMed Web of Science ®Google Scholar
• BonoraEFormentiniGCalcaterraFHOMA-estimated insulin resistance is an independent predictor of cardiovascular disease in type 2 diabetic subjects: prospective data from the Verona Diabetes Complications StudyDiabetes Care2002251135114112087010
   PubMed Web of Science ®Google Scholar
• TontonozPSpiegelmanBMFat and beyond: the diverse biology of PPAR-γAnn Rev Biochem20087728931218518822
   PubMed Web of Science ®Google Scholar
• RavnskjærKBørgesenMRubiBPeroxisome proliferator-activated receptor alpha (PPARalpha) potentiates, whereas PPARgamma attenuates, glucose-stimulated insulin secretion in pancreatic beta-cellsEndocrinology20051463266327615878969
   PubMed Web of Science ®Google Scholar
• SmithSAPeroxisome proliferator-activated receptors and the regulation of mammalian lipid metabolismBiochem Soc Trans200230(Pt 6):1086109012440979
   PubMed Web of Science ®Google Scholar
• OlefskyJMSaltielARPPAR gamma and the treatment of insulin resistanceTrends Endocrinol Metab20001136236811042466
   PubMed Web of Science ®Google Scholar
• FonsecaVARationale for the use of insulin sensitizers to prevent cardiovascular events in type 2 diabetes mellitusAm J Med20071209 Suppl 2S18S2517826042
   PubMed Web of Science ®Google Scholar
• LeiterLACan thiazolidinediones delay disease progression in type 2 diabetes?Curr Med Res Opin2006221193120116846552
   PubMed Web of Science ®Google Scholar
• CalkinACThomasMCPPAR agonists and cardiovascular disease in diabetesPPAR Res2008245410.
   PubMed Web of Science ®Google Scholar
• PatelCBDe LemosJAWyneKLMcGuireDKThiazolidinediones and risk for atherosclerosis: pleiotropic effects of PPARγ agonismDiabetes Vasc Dis Res200636571
   PubMedGoogle Scholar
• TurnerRCCullCAFrighiVHolmanRGlycemic control with diet, sulfonylurea, metformin, or insulin in patients with type 2 diabetes mellitus: progressive requirement for multiple therapies (UKPDS 49)JAMA19992812005201210359389
   PubMed Web of Science ®Google Scholar
• CookMNGirmanCJSteinPPAlexanderCMHolmanRRGlycemic control continues to deteriorate after sulfonylureas are added to metformin among patients with type 2 diabetesDiabetes Care200528995100015855556
   PubMed Web of Science ®Google Scholar
• AronoffSRosenblattSBraithwaiteSEganJWMathisenALSchneiderRLPioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study GroupDiabetes Care2000231605161111092281
   PubMed Web of Science ®Google Scholar
• ScherbaumWAGokeBMetabolic efficacy and safety of once-daily pioglitazone monotherapy in patients with type 2 diabetes: a double-blind, placebo-controlled studyHorm Metab Res20023458959512439788
   PubMed Web of Science ®Google Scholar
• HerzMJohnsDReviriegoJA randomized, double-blind, placebo-controlled, clinical trial of the effects of pioglitazone on glycemic control and dyslipidemia in oral antihyperglycemic medication-naive patients with type 2 diabetes mellitusClin Ther2003251074109512809958
   PubMed Web of Science ®Google Scholar
• LebovitzHEDoleJFPatwardhanRRappaportEBFreedMIfor the Rosiglitazone Clinical Trials Study GroupRosiglitazone monotherapy is effective in patients with type 2 diabetesJ Clin Endocrinol Metab20018628028811232013
   PubMed Web of Science ®Google Scholar
• PhillipsLSGrunbergerGMillerEfor the Rosiglitazone Clinical Trials Study GroupOnce- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetesDiabetes Care20012430831511213884
   PubMed Web of Science ®Google Scholar
• ChiquetteERamirezGDeFronzoRA meta-analysis comparing the effect of thiazolidinediones on cardiovascular risk factorsArch Intern Med20041642097210415505122
   PubMed Web of Science ®Google Scholar
• CharbonnelBHMatthewsDRSchernthanerGHanefeldMBrunettiPfor The QUARTET Study GroupA long-term comparison of pioglitazone and gliclazide in patients with type 2 diabetes mellitus: a randomized, double-blind, parallel-group comparison trialDiabet Med20052239940515787663
   PubMed Web of Science ®Google Scholar
• TanMHBaksiAKrahulecBfor the GLAL Study GroupComparison of pioglitazone and gliclazide in sustaining glycemic control over 2 years in patients with type 2 diabetesDiabetes Care20052854455015735185
   PubMed Web of Science ®Google Scholar
• HällstenKVirtanenKALönnqvistFRosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetesDiabetes2002513479348512453903
   PubMed Web of Science ®Google Scholar
• PavoIJermendyGVarkonyiTTEffect of pioglitazone compared with metformin on glycemic control and indicators of insulin sensitivity in recently diagnosed patients with type 2 diabetesJ Clin Endocrinol Metab2003881637164512679450
   PubMed Web of Science ®Google Scholar
• HanefeldMBrunettiPSchernthanerGHMatthewsDRCharbonnelBHfor the QUARTET Study GroupOne-year glycemic control with a sulfonylurea plus pioglitazone versus a sulfonylurea plus metformin in patients with type 2 diabetesDiabetes Care20042714114714693980
   PubMed Web of Science ®Google Scholar
• NagasakaSAisoYYoshizawaKIshibashiSComparison of pioglitazone and metformin efficacy using homeostasis model assessmentDiabet Med20042113614114984448
   PubMed Web of Science ®Google Scholar
• CharbonnelBSchernthanerGBrunettiPLong-term efficacy and tolerability of add-on pioglitazone therapy to failing monotherapy compared with addition of gliclazide or metformin in patients with type 2 diabetesDiabetologia2005481093110415889234
   PubMed Web of Science ®Google Scholar
• SchernthanerGMatthewsDRCharbonnelBHanefeldMBrunettiPfor the QUARTET Study GroupEfficacy and safety of pioglitazone versus metformin in patients with type 2 diabetes mellitus: a double-blind, randomized trialJ Clin Endocrinol Metab2004896068607615579760
   PubMed Web of Science ®Google Scholar
• KahnSEHaffnerSMHeiseMAfor the ADOPT Study GroupGlycemic durability of rosiglitazone, metformin, or glyburide mono-therapyN Engl J Med20063552427244317145742
   PubMed Web of Science ®Google Scholar
• TanMHJohnsDStrandJfor the GLAC Study GroupSustained effects of pioglitazone vs glibenclamide on insulin sensitivity, glycaemic control, and lipid profiles in patients with Type 2 diabetesDiabet Med20042185986615270789
   PubMed Web of Science ®Google Scholar
• National Institute for Health and Clinical Excellence (NICE)Type 2 diabetes: the management of type 2 diabetes (update) Available from: http://www.nice.org.uk/CG66 (accessed 17 October 2008).
   Google Scholar
• IDF Clinical Guidelines Task ForceGlobal guideline for type 2 diabetes: recommendations for standard, comprehensive, and minimal careDiabet Med20062357959316759299
   PubMed Web of Science ®Google Scholar
• RosenstockJRoodJCobitzABiswasNChouHGarberAInitial treatment with rosiglitazone/metformin fixed-dose combination therapy compared with monotherapy with either rosiglitazone or metformin in patients with uncontrolled type 2 diabetesDiabetes Obes Metab2006865066017026489
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBManagement of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapyDiabetologia2006491711172116802130
   PubMed Web of Science ®Google Scholar
• FonsecaVRosenstockJPatwardhanRSalzmanAEffect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitusJAMA20002831695170210755495
   PubMed Web of Science ®Google Scholar
• BaileyCJBagdonasARubesJRosiglitazone/metformin fixed dose combination compared with uptitrated metformin alone in type 2 diabetes mellitus: a 24 week, multicenter, randomized, double blind, parallel group studyClin Ther2005271548156116330291
   PubMed Web of Science ®Google Scholar
• HanefeldMPioglitazone and sulfonylureas: effectively treating type 2 diabetesInt J Clin Pract2007S1532027
   Google Scholar
• SmileyTThe role of declining beta cell function in the progression of type 2 diabetes: implications for outcomes and pharmacological managementCan J Diabetes200327277286
   Google Scholar
• GastaldelliAFerranniniEMiyazakiYMatsudaMMariADefronzoRAThiazolidinediones improve beta-cell function in type 2 diabetic patientsAm J Physiol Endocrinol Metab2007292E871E88317106061
   PubMed Web of Science ®Google Scholar
• JuhlCBHollingdalMPørksenNPrangeALönnqvistFSchmitzOInfluence of rosiglitizone treatment on β-cell function in type 2 diabetes: evidence of an increased ability of glucose to entrain high-frequency insulin pulsatilityJ Clin Endocrinol Metab2003883794380012915671
   PubMed Web of Science ®Google Scholar
• XiangAPetersRKjosSEffect of pioglitizone on pancreatic β-cell function and diabetes risk in Hispanic women with gestational diabetesDiabetes2006555172216443789
   PubMed Web of Science ®Google Scholar
• TripathyDBanerjiMABrayGAACTos NOW for the Prevention of Diabetes (ACT NOW) Study [Abstract]Diabetologia200851Suppl 1S99
   Google Scholar
• DREAM (Diabetes REduction Assessment with ramipril and rosiglitazone Medication) Trial InvestigatorsEffect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomised controlled trialLancet20063681096110516997664
   PubMed Web of Science ®Google Scholar
• GarberAKleinEBruceSSankohSMohideenPMetformin–glibenclamide versus metformin plus rosiglitazone in patients with type 2 diabetes inadequately controlled on metformin monotherapyDiabetes Obes Metab2006815616316448519
   PubMed Web of Science ®Google Scholar
• HamannAGarcia-PuigJPaulGDonaldsonJStewartMComparison of fixed-dose rosiglitazone/metformin combination therapy with sulfonylurea plus metformin in overweight individuals with type 2 diabetes inadequately controlled on metformin aloneExp Clin Endocrinol Diabetes200811661318095238
   PubMed Web of Science ®Google Scholar
• StewartMWCirkelDTFurusethKEffect of metformin plus roziglitazone compared with metformin alone on glycaemic control in well-controlled Type 2 diabetesDiabet Med2006231069107816978370
   PubMed Web of Science ®Google Scholar
• HomePDPocockSJBeck-NielsenHfor the RECORD Study GroupRosiglitazone evaluated for cardiovascular outcomes–an interim analysisN Engl J Med2007357283817551159
   PubMed Web of Science ®Google Scholar
• DorkhanMFridAA review of pioglitazone HCL and glimepiride in the treatment of type 2 diabetesVasc Health Risk Manag2007372173118078023
   PubMedGoogle Scholar
• DerosaGPioglitazone plus glimepiride: a promising alternative in metabolic controlInt J Clin Pract2007S1532836
   Google Scholar
• StaelsBMetformin and pioglitazone: Effectively treating insulin resistanceCurr Med Res Opin200622Suppl 2S27S3716914073
   PubMed Web of Science ®Google Scholar
• SeufertJA fixed-dose combination of pioglitazone and metformin: a promising alternative in metabolic controlCurr Med Res Opin200622Suppl 2S39S4816914074
   PubMedGoogle Scholar
• MatthewsDRCharbonnelBHHanefeldMBrunettiPSchernthanerGLong-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative studyDiabetes Metab Res Rev20052116717415386821
   PubMed Web of Science ®Google Scholar
• KerenyiZSamerHJamesRYanYStewartMCombination therapy with rosiglitazone and glibenclamide compared with upward titration of glibenclamide alone in patients with type 2 diabetes mellitusDiabetes Res Clin Pract20046321322314757293
   PubMed Web of Science ®Google Scholar
• ComaschiMDemicheliADi PietroCBellatrecciaAMarizSfor the COM06 Study InvestigatorsEffects of pioglitazone in combination with metformin or a sulfonylurea compared to a fixed-dose combination of metformin and glibenclamide in patients with type 2 diabetesDiabetes Technol Ther2007938739817705695
   PubMed Web of Science ®Google Scholar
• BetteridgeDJVergesBLong-term effects on lipids and lipoproteins of pioglitazone versus gliclazide addition to metformin and pioglitazone versus metformin addition to sulfonylurea in the treatment of type 2 diabetesDiabetologia2005482477248116283239
   PubMed Web of Science ®Google Scholar
• DerosaGCiceroAFGaddiAA comparison of the effects of pioglitazone and rosiglitazone combined with glimepiride on prothrombotic state in type 2 diabetic patients with the metabolic syndromeDiabetes Res Clin Pract20056951315955382
   PubMed Web of Science ®Google Scholar
• DerosaGGaddiAVPiccinniMNDifferential effect of glimepiride and rosiglitazone on metabolic control of type 2 diabetic patients treated with metformin: a randomized, double-blind, clinical trialDiabetes Obes Metab2006819720516448524
   PubMed Web of Science ®Google Scholar
• EinhornDRendellMRosenzweigJEganJWMathisenALSchneiderRLPioglitazone hydrochloride in combination with metformin in the treatment of type 2 diabetes mellitus: a randomized, placebo-controlled study. The Pioglitazone 027 Study GroupClin Ther2000221395140911192132
   PubMed Web of Science ®Google Scholar
• RosenblattSMiskinBGlazerNBPrinceMJRobertsonKEThe impact of pioglitazone on glycemic control and atherogenic dyslipidemia in patients with type 2 diabetes mellitusCoron Artery Dis20011241342311491207
   PubMed Web of Science ®Google Scholar
• MattooVEcklandDWidelMMetabolic effects of pioglitazone in combination with insulin in patients with type 2 diabetes mellitus whose disease is not adequately controlled with insulin therapy: results of a six-month, randomized, double-blind, prospective, multicenter, parallel-group studyClin Ther20052755456715978304
   PubMed Web of Science ®Google Scholar
• BerhanuPKipnesMSKhanMAEffects of pioglitazone on lipid and lipoprotein profiles in patients with type 2 diabetes and dyslipidaemia after treatment conversion from rosiglitazone while continuing stable statin therapyDiab Vasc Dis Res20063394416784180
   PubMedGoogle Scholar
• GoldbergRBKendallDMDeegMAA comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemiaDiabetes Care2005281547155415983299
   PubMed Web of Science ®Google Scholar
• DerosaGD’AngeloARagonesiPDMetformin–pioglitazone and metformin–rosiglitazone effects on non-conventional cardiovascular risk factors plasma level in type 2 diabetic patients with metabolic syndromeJ Clin Pharm Ther20063137538316882108
   PubMed Web of Science ®Google Scholar
• DeegMABuseJBGoldbergRBfor the GLAI Study InvestigatorsPioglitazone and rosiglitazone have different effects on serum lipoprotein particle concentrations and sizes in patients with type 2 diabetes and dyslipidemiaDiabetes Care2007302458246417595355
   PubMed Web of Science ®Google Scholar
• LawrenceJMReidJTaylorGJStirlingCRecklessJPFavorable effects of pioglitazone and metformin compared with gliclazide on lipoprotein subfractions in overweight patients with early type 2 diabetesDiabetes Care200427414614693964
   PubMed Web of Science ®Google Scholar
• PerezAKhanMJohnsonTKarunaratneMPioglitazone plus a sulfonylurea or metformin is associated with increased lipoprotein particle size in patients with type 2 diabetesDiabetes Vasc Dis Res200414450
   PubMedGoogle Scholar
• DerosaGD’AngeloARagnonesiPDEffects of rosiglitazone and pioglitazone combined with metformin on the prothrombotic state of patients with type 2 diabetes mellitus and metabolic syndromeJ Int Med Res20063454555517133785
   PubMed Web of Science ®Google Scholar
• GoldsteinBJWeissmanPNWooddellMJWaterhouseBRCobitzARReductions in biomarkers of cardiovascular risk in type 2 diabetes with rosiglitazone added to metformin compared with dose escalation of metformin: an EMPIRE trial sub-studyCurr Med Res Opin2006221715172316968575
   PubMed Web of Science ®Google Scholar
• PfutznerAMarxNLubbenGImprovement of cardiovascular risk markers by pioglitazone is independent from glycemic control: results from the PIONEER studyJ Am Coll Cardiol2005451925193115963388
   PubMed Web of Science ®Google Scholar
• YangWSJengCYWuTYSynthetic peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, increases plasma levels of adiponectin type 2 diabetic patientsDiabetes Care20022537638011815513
   PubMed Web of Science ®Google Scholar
• MazzoneTMeyerPMFeinsteinSBEffect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trialJAMA20062962572258117101640
   PubMed Web of Science ®Google Scholar
• NissenSENichollsSJWolskiKComparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trialJAMA20082991561157318378631
   PubMed Web of Science ®Google Scholar
• UK Prospective Diabetes Study (UKPDS) GroupEffect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34)Lancet19983528548659742977
   PubMed Web of Science ®Google Scholar
• WilcoxRBousserM-GBetteridgeDJfor the PROactive InvestigatorsEffects of pioglitazone in patients with type 2 diabetes with or without previous stroke: results from PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04)Stroke20073886587317290029
   PubMed Web of Science ®Google Scholar
• ErdmannEDormandyJACharbonnelBMassi-BenedettiMMoulesIKSkeneAMfor the PROactive InvestigatorsThe effect of pioglitazone on recurrent myocardial infarction in 2,445 patients with type 2 diabetes and previous myocardial infarction. Results from the PROactive (PROactive 05) studyJ Am Coll Cardiol2007491772178017466227
   PubMed Web of Science ®Google Scholar
• LincoffAMWolskiKNichollsSJNissenSEPioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trialsJAMA20072981180118817848652
   PubMed Web of Science ®Google Scholar
• NissenSEWolskiKEffect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causesN Engl J Med20073562457247117517853
   PubMed Web of Science ®Google Scholar
• Action to Control Cardiovascular Risk in Diabetes Study GroupGersteinHCMillerMEByingtonRPGoffDCJrBiggerJTEffects of intensive glucose lowering in type 2 diabetesN Engl J Med20083582545255918539917
   PubMed Web of Science ®Google Scholar
• DuckworthWCAmerican Diabetes Association 68th Scientific Sessions: VA Diabetes Trial SymposiumPresented 682008
   Google Scholar
• RaskinPRendellMRiddleMCDoleJFFreedMIRosenstockJfor the Rosiglitazone Clinical Trials Study GroupA randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetesDiabetes Care2001241226123211423507
   PubMed Web of Science ®Google Scholar
• BasuAJensenMDMcCannFMukhopadhyayDJoynerMJRizzaRAEffects of pioglitazone versus glipizide on body fat distribution, body water content, and hemodynamics in type 2 diabetesDiabetes Care2006951051416505497
   PubMedGoogle Scholar
• BaysHMandarinoLDeFronzoRARole of the adipocyte, free fatty acids, and ectopic fat in pathogenesis of type diabetes mellitus: peroxisomal proliferator-activated receptor agonists provide a rational therapeutic approachJ Clin Endocrinol Metab20048946347814764748
   PubMed Web of Science ®Google Scholar
• RyanMacular Edema associated with glitazoneRetina20062656257016770264
   PubMed Web of Science ®Google Scholar
• LiazosSpontaneous resolution of diabetic macular edema after discontinuation of thizolidinedionesDiabet Med20082586086218644073
   PubMed Web of Science ®Google Scholar
• KarallieddeJBuckinghamRStarkieMLorandDStewartMVibertiGfor the Rosiglitazone Fluid Retention Study GroupEffect of various diuretic treatments on rosiglitazone-induced fluid retentionJ Am Soc Nephrol2006173482349017093067
   PubMed Web of Science ®Google Scholar
• GreyABollandMGambleGThe peroxisome proliferator-activated receptor-γ agonist rosiglitazone decreases bone formation and bone mineral density in healthy postmenopausal women: a randomized, controlled trialJ Clin Endocrinol Metab2007921305131017264176
   PubMed Web of Science ®Google Scholar
• BerberogluZGursoyABayraktarNYaziciACBascil TutuncuNGuvener DemiragNRosiglitazone decreases serum bone-specific alkaline phosphatase activity in postmenopausal diabetic womenJ Clin Endocrinol Metab2007923523353017595249
   PubMed Web of Science ®Google Scholar
• GlintborgDAndersenMHagenCHeickendorffLHermannAPAssociation of pioglitazone treatment with decreased bone mineral density in obese premenopausal patients with polycystic ovary syndrome: a randomized, placebo-controlled trialJ Clin Endocrinol Metab2008931696170118285411
   PubMed Web of Science ®Google Scholar
• MeymehRHWooltortonEDiabetes drug pioglitazone (Actos): risk of fractureCMAJ200717772372417823139
   PubMed Web of Science ®Google Scholar
• YaturuSBryantBJainSKThiazolidinediones treatment decreases bone mineral density in type 2 diabetic menDiabetes Care2007301574157617363747
   PubMed Web of Science ®Google Scholar
• LauAHarperWThiazolidinediones and their effect on bone metabolism: a reviewCan J Diabetes200731378383
   Google Scholar
• StrattonIMAdlerAINeilHAAssociation of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational studyBMJ200032140541210938048
   PubMed Web of Science ®Google Scholar
• NathanDMBuseJBDavidsonMBFerranniniEHolmanRRSherwinRZinmanBMedical management of hyperglycaemia in type 2 diabetes: a consensus algorithm for the initiation and adjustment of therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of DiabetesDiabetes Care200932111
   Web of Science ®Google Scholar